

fee under 37 C.F.R. §§ 1.16 to 1.21 from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/4350.000800.

Reconsideration of the application in view of the following amendments and remarks is respectfully requested. Applicant believes that entry of the amendment herein is both timely and proper, as it addresses the remaining issues of the Office and places the case in condition for allowance.

1. AMENDMENT

1.1 IN THE CLAIMS:

Please amend claims 1-6, 8-9, 32-33, 37, 42-45, 47, 49-50, 61-63, and 67-75 so that the amended claims read as follows:

-
- C1
1. (Twice Amended) An isolated peptide of from 14 to about 70 amino acids in length, said peptide comprising the amino acid sequence of any one of SEQ ID NO:3 through SEQ ID NO:76.

 2. (Amended) The isolated peptide of claim 1, said peptide consisting essentially of the amino acid sequence of any one of SEQ ID NO:3 through SEQ ID NO:76.

 - C2
3. (Amended) ~~An isolated peptide of from 14 to about 50 amino acids in length, said peptide comprising the amino acid sequence of any one of SEQ ID NO:3 through SEQ ID NO:55 or any one of SEQ ID NO:58 through SEQ ID NO:76.~~

 4. (Amended) An isolated peptide of from 14 to about 40 amino acids in length, said peptide comprising the amino acid sequence of any one of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:15 through SEQ ID NO:52, SEQ ID NO:58 through SEQ ID NO:67, or SEQ ID NO:74 through SEQ ID NO:76.

5. (Amended) An isolated peptide of from 14 to about 30 amino acids in length, said peptide comprising the amino acid sequence of any one of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:25 through SEQ ID NO:50, or SEQ ID NO:74 through SEQ ID NO:76.

C-2
C-3
6. (Amended) An isolated peptide of from 14 to about 20 amino acids in length, said peptide comprising the amino acid sequence of any one of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:46 through SEQ ID NO:50.

C-3
8. (Twice Amended) An isolated peptide consisting essentially of the amino acid sequence of any one of SEQ ID NO:3 through SEQ ID NO:76.

9. (Twice Amended) An isolated peptide consisting of the amino acid sequence of any one of SEQ ID NO:3 through SEQ ID NO:36.

C-4
32. (Thrice Amended) The isolated peptide of claim 1, or the polypeptide of claim 12, further comprising at least one detectable label.

33. (Thrice Amended) The isolated peptide or polypeptide of claim 32, wherein said at least one detectable label is a radiolabel, a chromogenic label, a fluorescent label or a labelled secondary antibody that specifically binds to said peptide or said polypeptide.

C-5
37. (Amended) The isolated peptide or polypeptide of claim 36, wherein said fluorescent protein comprises at least one green fluorescent protein or at least one humanized green fluorescent protein.

C-6
42. (Thrice Amended) A composition-comprising: the isolated peptide of claim 1, or the polypeptide of claim 12.

43. (Amended) The composition of claim 42, further comprising at least one pharmaceutically-acceptable excipient.

C-7
44. (Amended) The composition of claim 42, further comprising at least one immunostimulant or at least one adjuvant.

45. (Amended) The composition of claim 44, wherein said at least one immunostimulant or said at least one adjuvant is selected from the group consisting of a cytokine, a

C7
cont

microsphere, Ribi Adjuvant, saponin, a microfluidized adjuvant, an immune stimulating complex, and an inactivated toxin.

C9

47. (Amended) The composition of claim 42, further comprising at least one detection reagent.

C9

49. (Amended) The composition of claim 48, wherein said at least one detection reagent specifically binds to (a) a p33^{QIK} peptide or polypeptide; (b) a p63^{KrsI} peptide or polypeptide, (c) an antibody or an antigen binding fragment specific for a p33^{QIK} peptide or polypeptide, or (d) an antibody or an antigen binding fragment specific for a p63^{KrsI} peptide or polypeptide.

50. (Amended) A kit comprising the isolated peptide of claim 1, the isolated polypeptide of claim 12, or an antibody or an antigen binding fragment specific for either the isolated peptide of claim 1 or the isolated polypeptide of claim 12; and instructions for using said kit.

C10

61. (Amended) The isolated peptide of claim 66, said peptide consisting of the amino acid sequence of SEQ ID NO:3.

62. (Amended) The isolated peptide of claim 66, said peptide consisting of the amino acid sequence of SEQ ID NO:4.

63. (Amended) The isolated peptide of claim 66, said peptide consisting of the amino acid sequence of any one of SEQ ID NO:5 through SEQ ID NO:36.

C11

67. (Amended) An isolated peptide of from 14 to approximately 50 amino acids in length, said peptide comprising the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

68. (Amended) The isolated peptide of claim 67, wherein said peptide is from 14 to approximately 45 amino acids in length.

69. (Amended) The isolated peptide of claim 67, wherein said peptide is from 14 to approximately 40 amino acids in length.

70. (Amended) The isolated peptide of claim 67, wherein said peptide is from 14 to approximately 35 amino acids in length.
71. (Amended) The isolated peptide of claim 67, wherein said peptide is from 14 to approximately 30 amino acids in length.
72. (Amended) The isolated peptide of claim 67, wherein said peptide is from 14 to approximately 25 amino acids in length.
73. (Amended) An isolated peptide of from 14 to approximately 70 amino acids in length, said peptide comprising the amino acid sequence of any one of SEQ ID NO:3 through SEQ ID NO:76.
74. (Amended) An isolated peptide of from 14 to approximately 60 amino acids in length, said peptide comprising the amino acid sequence of any one of SEQ ID NO:3 through SEQ ID NO:76.
75. (Amended) An isolated peptide of from 14 to approximately 50 amino acids in length, said peptide comprising the amino acid sequence of any one of SEQ ID NO:3 through SEQ ID NO:76.
- C 11
Cone

2. RESPONSE

2.1 STATUS OF THE CLAIMS

(Re: the Action, Items 1-3)

Claims 1-9, 12, 32-37, 42-52, and 61-75 were pending at the time of the Action.

Claims 1-6, 8-9, 32-33, 37, 42-45, 47, 49-50, 61-63, and 67-75 were amended herein.

Claims 1-9, 12, 32-37, 42-52 and 61-75 remain pending in the case.

Claims 12 and 66 have been allowed as follows:

12. (Allowed) An isolated polypeptide consisting of the amino acid sequence from position 1 to position 322 of SEQ ID NO:2.